

Silva Pharmaceuticals Limited

Un-Audited Financial Statements (First Quarter)

For the Period from 01 July, 2020 to 30 September, 2020

Silva Pharmaceuticals Limited

Statement of Financial Position (Un-Audited)

As at 30 September, 2020

Particulars	Notes	Amount in Taka	
		30-Sep-20	30-Jun-20
ASSETS			
Non Current Assets		1,398,831,097	1,365,926,835
Property, Plant and Equipment	3.00	1,210,457,709	1,221,249,900
Intangible Assets	4.00	1,265,908	1,178,827
Right-of-use asset (ROU)	5.00	20,353,139	21,712,480
Capital work-in-Progress	6.00	166,754,341	121,785,628
Current Assets		1,122,954,648	1,090,279,961
Inventories	7.00	449,965,728	444,378,778
Trade and Other Receivables	8.00	268,054,704	263,426,843
Advances, Deposits and Prepayments	9.00	159,535,374	143,026,882
Fixed Deposits Receipts (FDR)		203,307,341	203,035,178
Cash and Cash Equivalents	10.00	42,091,501	36,412,280
Total Assets		2,521,785,745	2,456,206,796
SHAREHOLDERS EQUITY AND LIABILITIES:			
Equity attributable to the Shareholders		2,245,281,588	2,198,109,877
Share Capital	11.00	1,365,000,000	1,365,000,000
Retained Earnings	12.00	880,281,588	833,109,877
Non-Current Liabilities		98,077,466	98,260,873
Deferred Tax Liabilities	13.00	85,927,269	84,977,387
Lease liabilities	14.00	12,150,197	13,283,486
Current Liabilities		178,426,691	159,836,046
Lease liabilities	14.00	5,496,342	5,722,394
Trade and Other Payables	15.00	7,480,719	7,869,837
Short Term Loan		28,157,712	26,680,475
Provision for Expenses	16.00	137,291,918	119,563,340
Total Liabilities		276,504,157	258,096,919
Total Equity & Liabilities:		2,521,785,745	2,456,206,796
Net Assets Value (NAV) per share	22.00	16.45	16.10


Chairman


Managing Director


Director


Chief Financial Officer


Company Secretary

Silva Pharmaceuticals Limited

Statements of Profit or Loss and other Comprehensive Income (Un-Audited)

For the First Quarter ended 30 September, 2020


Particulars	Notes	Amount in Taka	
		July - September, 2020	July - September, 2019
Turnover		227,521,337	203,345,852
Cost of goods sold	17.00	(127,252,357)	(117,490,189)
Gross Profit		100,268,980	85,855,663
Operating expenses	18.00	(37,302,643)	(35,454,111)
Operating Income		62,966,337	50,401,552
Financial expenses		(682,039)	-
Net Operating Profit		62,284,298	50,401,552
Interest and Other income		3,797,573	5,878,968
Net Profit before Contribution to WPPF		66,081,871	56,280,520
Worker's Profit Participation fund (WPPF)	19.00	(3,146,756)	(2,680,025)
Net Profit before Income Tax		62,935,115	53,600,495
Income Tax Expenses:		(15,763,404)	(13,400,124)
Current Tax Expenses	20.01	(14,813,522)	(12,009,028)
Deferred Tax expenses	20.02	(949,882)	(1,391,096)
Net Profit after tax		47,171,711	40,200,371
Other Comprehensive Income		-	-
Total comprehensive income for the year		47,171,711	40,200,371
Earnings per Share (EPS)	21.00	0.35	0.29



Chairman



Managing Director



Director



Chief Financial Officer




Company Secretary

Silva Pharmaceuticals Limited
Statement of Changes in Equity (Un-Audited)
For the First Quarter ended 30 September, 2020

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2020	1,365,000,000	833,109,877	2,198,109,877
Net profit after tax during the period	-	47,171,711	47,171,711
Balance as at 30 September, 2020	1,365,000,000	880,281,588	2,245,281,588

Silva Pharmaceuticals Limited
Statement of Changes in Equity
For the First Quarter ended 30 September, 2019

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2019	1,300,000,000	833,442,946	2,133,442,946
Net profit after tax during the period	-	40,200,371	40,200,371
Balance as at 30 September, 2019	1,300,000,000	873,643,317	2,173,643,317



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary

Silva Pharmaceuticals Limited

Statement of Cash Flows (Un-Audited)

For the First Quarter ended 30 September, 2020

Particulars	Amount in Taka	
	July - September, 2020	July - September, 2019
Cash flows from Operating Activities		
Cash received from Customers	225,917,479	193,166,710
Cash received from non-operating income	773,570	1,428,508
Cash Paid to Suppliers	(117,915,717)	(112,749,278)
Cash Paid to Employees	(31,535,804)	(28,499,149)
Cash Paid for Others	(7,517,985)	(6,866,360)
Income Tax Paid	(12,732,908)	(10,645,856)
Net cash inflow/(outflow) from operating activities (A)	56,988,635	35,834,575
Cash flows from Investing Activities		
Acquisition of Property, Plant and Equipment	(5,504,395)	(13,727,535)
Cash Payments for Capital Work-in-progress	(44,968,713)	(16,649,506)
Cash Payments for FDR	(272,163)	(6,500,000)
Net cash inflow/(outflow) from investing activities (B)	(50,745,271)	(36,877,041)
Cash flows from Financing Activities		
Short Term Loan received/(Repaid)	1,477,237	-
Cash payment for Financial Expenses	(418,260)	-
Cash payment towards lease liabilities	(1,623,120)	-
Net cash used in financing activities (C)	(564,143)	-
Net increase/(decrease) of Cash and Cash Equivalents (A+B+C)	5,679,221	(1,042,466)
Cash and Cash Equivalents at the beginning of the period	36,412,280	42,391,451
Cash and Cash Equivalents at the end of the period	42,091,501	41,348,985
Net Operating Cash Flows Per Share	23.00	0.42
		0.26



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary